Evidence map›Paper›PMID 37307250›Full record

ArticlePloS one2023

Analysis of clozapine-induced seizures using the Japanese Adverse Drug Event Report database.

Masakazu Hatano, Kaho Yamada, Haruna Matsuzaki, Rina Yokoi, Takeo Saito, Shigeki Yamada

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Article
  9. Observational
  10. A Pharmacovigilance Study on Clozapine in the Food and Drug Administration Adverse Event Reporting System: A Regional Comparative Analysis.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024
    Article
  11. Do psychotropic drugs cause seizures?Epilepsy & behavior reports · 2024
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Masakazu HatanoDepartment of Pharmacotherapeutics and informatics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.ORCID 0000-0001-7032-878X
Kaho YamadaDepartment of Pharmacotherapeutics and informatics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Haruna MatsuzakiDepartment of Pharmacotherapeutics and informatics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Rina YokoiDepartment of Pharmacotherapeutics and informatics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Takeo SaitoDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Shigeki YamadaDepartment of Pharmacotherapeutics and informatics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Fujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among antipsychotics, clozapine is associated with a high risk of seizures. This study aimed to generate novel hypotheses regarding trends in the onset of clozapine-induced seizures using the JADER (Japanese Adverse Drug Event Report) database. Seizures were defined according to the Standardized MedDRA Queries (SMQ) for convulsions (SMQ20000079). Trends in the onset of clozapine-induced seizures were assessed using multivariate logistic regression analysis with covariates of sex, age, clozapine dose, antipsychotic polypharmacy, concomitant medications, and history of convulsive disorder. In addition, we assessed the time-to-onset of clozapine-induced seizures using the median time, interquartile range, and Weibull shape parameter. The JADER database registered 2,745 cases of adverse events with clozapine, and 1,784 cases were included in the analysis after excluding cases for which clinical information was not available. Medium (200-400 mg) and high (> 400 mg) doses of clozapine had a significantly higher reporting rate of seizures than low doses (< 200 mg) (adjusted reporting odds ratio [aROR] = 3.05, 95% confidence interval [CI]: 1.86-4.99 and aROR = 9.81, 95% CI: 6.06-15.89, respectively). Younger age, antipsychotic polypharmacy, and concomitant use of lithium were also significantly associated with reports of seizures. The time-to-onset analysis of 222 cases of clozapine-induced seizures showed that the median time was 134 (interquartile range, 72-295) days. The 95% CI of the WSP β-value for clozapine-induced seizures included 1 and was classified as a random failure type. In conclusion, the results suggest that clozapine-induced seizures are dose-dependent adverse events that should be monitored with consideration of the effects of age and concomitant medications. Further epidemiological research is needed to strengthen and validate our hypotheses.

Indexed as

Antipsychotic AgentsClozapineDrug-Related Side Effects and Adverse ReactionsSeizuresEast Asian PeopleHumansJapanAntipsychotic AgentsClozapine

Identifiers

PMID37307250
PMCPMC10259781
OpenAlexW4380303620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.